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Abstract
Background Survival after cardiopulmonary resuscitation
(CPR) using standard vasopressor therapy is disappointing.
Vasopressin is a potent vasopressor that could become a
useful therapeutic alternative in the treatment of cardiac
arrest.
Aims The aim of this prehospital prospective cohort study
was to assess the influence of treatment with vasopressin
and hydroxyethyl starch solution (HHS) on outcome in
resuscitated blunt trauma patients with pulseless electrical
activity (PEA) cardiac arrest.
Methods Two treatment groups of resuscitated trauma
patients in cardiac arrest were compared: in the epinephrine
group patients received epinephrine 1 mg IV every 3 min
only; in the vasopressin group patients first received
hypertonic HHS and arginine vasopressin 40 units IV only
or followed by epinephrine 1 mg every 3 min until cessation
of CPR. Medical trauma care was provided according to
advanced trauma life support (ATLS) guidelines.
Results The study included 31 patients and there were no
significant demographic or clinical differences between the
treatment groups. Significantly more circulatory restorations
[11/13(85%)vs3/18(17%);P<0.01] and better 24-h survival
rates [8/13 (62%) vs 2/18 (11%); P=0.001] were observed
in the vasopressin group. Average mean arterial pressure
(100.4±11.4 mmHg vs 80.3±12.4 mmHg) and final end-
tidal partial pressure of carbon dioxide (PETCO2)a t
admission (4.5±0.9 kPa vs 2.8±0.4 kPa) were also higher
in the vasopressin group.
Conclusion Our results suggest that victims of severe blunt
trauma with PEA should be initially treated with vasopres-
sin in combination with HHS volume resuscitation fol-
lowed by standard resuscitation therapy and other
procedures when appropriate. Vasopressin might be poten-
tially lifesaving in blunt trauma cardiac arrest compared to






Survival after cardiopulmonary resuscitation (CPR) using
standard vasopressor therapy is disappointing. Side effects
of epinephrine such as increased myocardial oxygen
demand and consumption, decreased myocardial ATP with
proarrhythmic effects, or increased intrapulmonary shunting
and myocardial dysfunction during the post-resuscitation
period are well known [1, 2]. Vasopressin is a potent
vasopressor that could become a useful therapeutic alterna-
tive in the treatment of cardiac arrest, because it signifi-
cantly improves total cerebral and left myocardial blood
flow, and it causes a sustained increase in mean arterial
blood pressure as compared with maximal doses of
epinephrine. Recent studies have shown that during CPR
vasopressin is especially beneficial when combined with
epinephrine [3–6]. Survival after traumatic cardiac arrest is
very poor, and some consider resuscitation of such patients
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e-mail: grmec-mis@siol.netfutile, especially in patients with hypovolemia as the
primary cause of arrest [7–12]. In spite of that some studies
were performed [13–15] in which successful hemodynamic
stabilization occurred using vasopressin in uncontrolled
hemorrhagic shock and during traumatic CPR.
We conducted a clinical investigation to assess the effect
of vasopressin and hydroxyethyl starch solution (HHS) on
outcome of out-of-hospital CPR in blunt trauma patients,
who had pulseless electrical activity (PEA) cardiac arrest.
Our hypothesis was that vasopressin improves outcome
in PEA cardiac arrest caused by blunt trauma.
Patients and methods
We undertook a prospective observational cohort study,
with a retrospective control group, in a prehospital setting,
after approval had been granted by the Ethics Review
Board of the Ministry of Health of Slovenia. The study
design of a prospective cohort with retrospective historical
controls is useful as forming the basis for recommending
prospective multicenter trials on an important issue. The
study community, in the region surrounding the city of
Maribor in Slovenia, includes a population of 190,000, and
approximately 90 resuscitations are attempted per year.
Initial basic and advanced cardiac life support is provided
by emergency doctors before the patient’s arrival at the
hospital (prehospital emergency unit), applying a regional
protocol that incorporates European Resuscitation Council
standards, guidelines, and clinical algorithms for CPR.
This study included trauma patients in cardiac arrest with
registered initial PEA < 40 waves/min only. Two groups of
resuscitated patients were compared. Patients in group 1
received epinephrine 1 mg every 3 min only (data were
collected from January 1998 to November 2002). Patients
in group 2 first received 40 IU of arginine vasopressin from
250 ml Pitressin™ formulation (Goldshield Pharmaceuti-
cals, Croydon, UK) in combination with HHS 4 ml/kg,
followed by epinephrine 1 mg every 3 min if circulation
was not restored before (data were collected from Decem-
ber 2002 to December 2006). All drugs were injected as an
intravenous bolus followed by 20 ml of normal saline.
Exclusion criteria were age under 18 years, documented
terminal illness, nontraumatic cardiac arrest, and severe
hypothermia (<30°C). Diagnoses were confirmed in the
intensive care unit, or, for those patients who died at the
scene, at autopsy. The data regarding CPR in the prehospi-
tal setting were collected in accordance with directions
presented by the International Liaison Committee on
Resuscitation (ILCOR) Task Force on Cardiac Arrest and
Cardiopulmonary Resuscitation Outcomes.
Data are expressed as mean±standard deviation or number
(%). Comparisons between groups were performed using
Fisher’s exact test for categorical data and Wilcoxon’sr a n k
sum test for numerical data. The null hypothesis was
considered to be rejected at P values less than 0.05. Multiple
logistic regression analysis was done to examine the relation-
shipbetweensurvivalandapplicationofvasopressin,adjusting
for age, sex, time elapsed before CPR, time of resuscitation by
the medical team, witnessed arrest, and basic life support by
bystanders. The results are expressed as odds ratio with 95%
confidence interval. All analyses were conducted using SPSS
version 12.0 software (SPSS, Inc., Chicago, IL, USA).
Results
A Utstein reporting template for out-of-hospital cardiac arrest
in Maribor obtained in a 9-year period is show in Fig. 1.
The study included 31 patients and there were no
significant demographic or clinical differences between the
groups regarding gender, age, first monitored rhythm,
location of arrest, arrest witnessed, bystander CPR, response
time, initial end-tidal partial pressure of carbon dioxide
(PETCO2) and Injury Severity Score (ISS) at admission
(Table 1). There were 18 patients in the epinephrine group 1
and 13 patients in the vasopressin group 2.
Inthevasopressin groupsignificantlymore restorationsof
circulation [11/13 (85%) vs 3/18 (17%); P<0.01] and better
24-h survival rates [8/13 (62%) vs 2/18 (11%); P=0.001]
were observed.
The discharge rate from hospital was also better, but not
statisticallly significant, in the vasopressin group [4/13
(31%) vs 1/18 (6%); P=0.13] (Table 1).
Average final mean arterial pressure (MAP) at admission
to hospital was higher in the vasopressin group (100.4±
11.4 mmHg) compared to the epinephrine group (80.3±
12.4 mmHg). Final PETCO2 was also higher in the
vasopressin group (4.5±0.9 kPa vs 2.8±0.4 kPa; P<0.01)
(Table 1). In the vasopressin group seven patients received
only vasopressin 40 IU and nine patients received addi-
tional epinephrine therapy.
The variables associated with restoration of spontaneous
circulation (ROSC) were: response time, witnessed arrest,
bystander CPR, average dose of epinephrine, ISS, initial
and average PETCO2, and vasopressin therapy (Table 2).
The variables associated with survival and hospital dis-
charge were: response time, witnessed arrest, bystander
CPR, average dose of epinephrine, initial and average
PETCO2, initial and final MAP, and ISS (Table 3).
Discussion
Our research supports the role of vasopressin as an efficient
vasopressor during out-of-hospital CPR in blunt trauma
312 Int J Emerg Med (2008) 1:311–316Table 1 Demographic and clinical characteristics of out-of-hospital traumatic cardiac arrest patients in the vasopressin and epinephrine groups
Epinephrine (historical)
group (N = 18)
Vasopressin (prospective)
group (N = 13)
P value
Gender: male/female 14/4 10/3 0.99
Age 43.2±19.9 (18–83) 44.9±23.2 0.79
Location of arrest: public place/home/workplace 11/2/5 8/1/4 0.82
Mechanism of injury: traffic incident/fall-jump/blow-assault/other 7/6/3/2 6/4/2/1 0.78
Arrest witnessed: yes/no 13/5 9/4 0.99
Bystander CPR: yes/no 7/11 3/10 0.71
Response time: call to start with CPR (min) 8±5 9±4 0.93
Initial PETCO2 (kPa) 0.93±0.58 0.98±0.49 0.89
Initial MAP (mmHg) after ROSC 75.2±12.2 94.5±10.2 <0.01
Resuscitation by medical team (min) 28.8±8.9 18.6±8.1 <0.01
ROSC (%) 3/15 (17%) 11/13 (85%) <0.001
24-h survival rate (%) 2/18 (11%) 8/13 (62%) 0.001
Average volume of resuscitation (without HHS) (ml) 2,722±951 1,744±548 <0.01
Average dose of epinephrine (mg) 7.8±3.8 4.3±2.7 <0.01
ISS at admission: median (percentile 25 and 75) 24 (17, 27) 23 (16, 26) 0.95
Final MAP at admission (mmHg) 80.3±12.4 100.4±11.4 <0.01
Final PETCO2 at admission (kPa) 2.8±0.4 4.5±0.9 <0.01
Discharge alive from hospital 1/18 (6%) 4/13 (31%) 0.13
CPR cardiopulmonary resuscitation, PETCO2 end-tidal partial pressure of carbon dioxide, MAP mean arterial blood pressure, ROSC restoration of
spontaneous circulation, ISS Injury Severity Score
Absence of signs of cirulation and/or considered for  resuscitation 
n = 1173 
Aetiology 
Presumed cardiac        n = 528 
Trauma                         n = 49 
Submersion                  n = 32 
Respiratory                  n = 77 
Other noncardiac         n = 62 
Unknown                     n = 40 
Resuscitation not 
attempted 
All cases                   n = 385 
Resuscitation 
attempted 
All cases                             n = 788 
Any defibrillation attempt  n = 451 
Chest compressions    n = 764 
Assisted ventilation n = 772
First monitored 
rhythm 
Shockable                      n = 316 
VF             n = 278 
VT             n = 38 
Nonshockable                n = 472 
Asystole     n = 301 
PEA           n = 171 
Unknown n = 0
Location of arrest 
Out – of – hospital    n = 788 
     Home                    n = 412 
     Public place          n = 272 
     Other                    n =  104 
Distribution of arrest
City                     n = 513 
     Rural                  n = 275       
Arrest witnessed/monitored   n = 581 
By layperson/ bystander            n = 493 
By healthcare personnel            n = 88 
Arrest not witnessed                n = 207 
CPR before EMS arrival        n = 187  Outcome (recorded for all categories) 
Any ROSC 
Yes                          n = 480 
No                            n = 308 
Unknown                 n =  0 
Survived event                    n = 378 
Discharged alive                 n =  173 
Neurologic outcome at discharge 
CPC 1 or 2              n = 108 
CPC 3 or 4              n = 59 
            CPC 5                    n = 6 
Fig. 1 Utstein reporting
template for out-of-hospital
cardiac arrest in Maribor
obtained in a 9-year period
Int J Emerg Med (2008) 1:311–316 313patients, who are in cardiac arrest with initial PEA. In our
previous studies about prehospital CPR we established the
relationship between PETCO2, MAP, and the prognosis [5,
6]. The average and final PETCO2 in vasopressin-treated
patients with ROSC were significantly higher as well as the
initial and the final MAP values. Therefore, vasopressin
could be more potent than epinephrine in increasing the
cardiac output. Results from the study by Bell and
colleagues [16] indicate that to secure cerebral perfusion
and prevent secondary cerebral injury MAP should be kept
at a level higher than commonly accepted. In our study,
MAP was kept at a normal level (approximately
100 mmHg), thus securing coronary perfusion and preserv-
ing cerebral perfusion in the critical post-resuscitation
period of absent cerebral autoregulation.
Some studies confirmed that the traumatic cardiac or
pulmonary arrest is often associated with a dismal outcome
and is considered to be an example of medical futility and
inappropriate use of resources [7–11]. On other hand, the
use of guidelines regarding the termination or withholding
of CPR in traumatic cardiac arrest patients remains
controversial because several survivors met criteria for
nontreatment according to the proposed clinical guidelines
[8, 12]. Vasopressin is a promising agent in the treatment of
traumatic cardiac arrest, especially in hemorrhagic shock
[17]. Voelckel et al. in two experimental studies [13, 14]
concluded that treatment of hypovolemic cardiac arrest with
vasopressin, but not epinephrine, resulted in sustained vital
organ perfusion with less metabolic acidosis in the post-
resuscitation phase, decreased gut perfusion in the post-
resuscitation phase without impairing renal function, and
subsequently in improved survival. Similarly, Sanui et al.
[15, 18] have found that early supplemental arginine
vasopressin (AVP) rapidly corrected cerebral perfusion
pressure, improved cerebrovascular compliance, and pre-
vented circulatory collapse during fluid resuscitation of
hemorrhagic shock after traumatic brain injury. In severe
chest trauma early AVP decreased mortality, reduced fluid
requirements, improved pulmonary function, and did not
increase the risk for bleeding in uncontrolled hemorrhage
[19]. In case reports of uncontrolled hemorrhagic shock
with subsequent cardiac arrest some authors confirmed
these results [20, 21].
The study by Friesenecker and colleagues [22] showed
that, under normal physiological conditions, vasopressin
exerted significantly stronger vasoconstriction on large
arterioles than norepinephrine.
This observation could explain, in part, why vasopressin
can be effective in advanced shock unresponsive to
therapeutic increases of catecholamines. In a clinical study,
Westerman et al. [23] confirmed significantly increased
levels of endogenous vasopressin in multiple trauma
patients.
That seems to be an integral part of the neuroendocrine
response to severe injury; therefore, the natural response to
trauma may be enhanced by additional exogenous vaso-
pressin. Some clinical observations suggest that endoge-
nous vasopressin insufficiency may be an underlying
mechanism of refractory hypotension after prolonged
hemorrhagic shock. Another beneficial effect of vasopres-
sin may be that the blood is shifted away from a
subdiaphragmatic region to the heart and brain, thus
optimizing vital organ perfusion. This effect of vasopressin
may be especially lifesaving in patients with uncontrolled
hemorrhage resulting from subdiaphragmatic injury [24–
28]. In the historical group, resuscitation efforts lasted
longer and a significantly higher quantity of additional
epinephrine was needed. Adrenergic stimulation by addi-
tional doses of epinephrine is associated with adverse
cardiac effects, including post-resuscitation myocardial
dysfunction and increased myocardial oxygen consump-
Table 3 Variables associated with survival (discharge form hospital)






Response time 1.52 1.25–3.36 0.009
Witnessed arrest 5.74 2.23–17.85 <0.001
Bystander CPR 4.16 1.67–8.85 <0.001
Initial PETCO2 1.72 1.33–3.08 0.013
Average PETCO2 1.45 1.25–2.02 0.022
Final PETCO2 2.83 1.62–4.27 <0.001
Initial MAP (after ROSC) 1.49 1.27–2.12 0.03
Final MAP (at admission) 1.68 1.35–2.58 0.021
Vasopressin 1.32 0.89–1.65 0.48
ISS 2.53 1.47–3.28 0.003
Average dose of epinephrine 1.49 1.21–2.96 0.02
Average volume of resuscitation
(without HHS)
1.13 0.78–2.37 0.38
Table 2 Variables associated with restoration of spontaneous circu-






Response time 1.43 1.19–3.12 0.013
Witnessed arrest 1.56 1.85–4.22 0.011
Bystander CPR 2.65 1.48–5.36 0.004
Initial PETCO2 18.72 5.12–33.87 <0.001
Average PETCO2 6.84 2.33–8.68 <0.001
Vasopressin 3.86 1.54–5.24 0.003
ISS 1.58 1.22–3.86 0.01
Average volume of resuscitation
(without HHS)
1.16 0.86–3.32 0.28
Average dose of epinephrine 1.86 1.43–4.12 0.011
314 Int J Emerg Med (2008) 1:311–316tion. In our trial in the vasopressin group we combined
vasopressin with hypertonic HHS. Søreide and Deakin
reported [29] that the ideal prehospital fluid regimen may
be a combination of an initial hypertonic solution given as a
10- to 20-min infusion, followed by crystalloids, and in
some cases, artificial colloids. Meybohm et al. [27, 30]
suggested the combination of HHS and vasopressin
during the initial 10 min of therapy; cerebral perfusion
pressure of the HHS group was significantly higher
compared to the fluid group and increased more rapidly
in the HHS with vasopressin group. HHS has a positive
effect on hemodynamic parameters (systemic vascular
resistence index, pulmonary vascular resistence index),
microcirculation, and oxygen transport [31]. The inter-
esting study of Giusti-Paiva et al. can explain one
additional synergistic effect of HHS and vasopressin
[32]. In this study they confirmed the effects of hypertonic
saline solution administration on vasopressin secretion and
mean arterial pressure in endotoxic shock. The hypertonic
saline administration was followed by an immediate
recovery of blood pressure and also by an increase in
plasma vasopressin levels compared with isotonic saline
solution. The vasopressin V1 receptor antagonist blocked
the pressor response to hypertonic saline solution. These
data suggest that the recovery of blood pressure after
hypertonic saline solution administration during endotoxic
s h o c ki sm e d i a t e db yv a s o p r e s s i ns e c r e t i o n .M a y b ea
similar mechanism was responsible for the positive effect
of HHS and vasopressin in traumatic cardiac arrest. The
higher initial MAP after ROSC and lower average dose of
epinephrine and average volume of resuscitation (without
HHS) with similar ISS in both groups suggest that
vasopressin could be more potent than epinephrine in
increasing the cardiac output.
This small study has all the inherent problems associated
with observational studies, but despite these limitations
suggests a resuscitation strategy involving vasopressin in
combination with HHS as a potentially lifesaving treatment
in blunt trauma cardiac arrest. Our observations should be
confirmed in future by larger multicenter prospective
clinical trials.
Conclusion
Survival after traumatic cardiac arrest is in general
extremely rare. Our study showed better short-term survival
in blunt trauma patients with PEA cardiac arrest, who were
resuscitated using vasopressin in combination with HHS.
Variables associated with survival and hospital discharge
were: response time, witnessed arrest, bystander CPR,
initial and average PETCO2, initial and final MAP, and
ISS. Vasopressin in combination with HHS might be
potentially lifesaving in blunt trauma cardiac arrest com-
pared to standard treatment with epinephrine.
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